Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation

6 Aug 2022

Abstract excerpt

A number of genetic risk factors have been identified over the past decade for Parkinson's Disease (PD), with variants in GBA prominent among them. GBA encodes the lysosomal enzyme that degrades the glycosphingolipid, glucosylceramide (GlcCer), with the activity of this enzyme defective in Gaucher disease. Based on the ill-defined relationship between glycosphingolipid metabolism and PD, we now analyze levels of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Lysosomal Storage Disorders Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35933559
DOI: 10.1038/s41531-022-00363-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutationPMID 35933559Read ↗

Shared and Distinct Lipid Profiles in amygdala from Sporadic and GBA-associated Parkinson’s DiseasesSemantic proximity Read ↗

Serum lipid alterations in GBA-associated Parkinson's disease.Semantic proximity Read ↗

GBA mutations, glucosylceramide and Parkinson's disease.Semantic proximity Read ↗

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.Semantic proximity Read ↗

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted TherapySemantic proximity Read ↗

Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics.Semantic proximity Read ↗

The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s diseaseSemantic proximity Read ↗

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s diseaseSemantic proximity Read ↗

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutationSemantic proximity Read ↗

Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.Semantic proximity Read ↗

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.